Zheng Xiangqin, Lin Danmei, Zhang Yulong, Lin Yuan, Song Jianrong, Li Suyu, Sun Yan
Department of Obstetrics and Gynecology, Fujian Provincial Maternity and Children's Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Medicine (Baltimore). 2017 Dec;96(49):e8842. doi: 10.1097/MD.0000000000008842.
Pretreatment of myoinositol is a very new method that was evaluated in multiple small studies to manage poor ovarian response in assisted reproduction. This study was to determine the efficacy of myoinositol supplement in infertile women undergoing ovulation induction for intracytoplasmic sperm injection (ICSI) or in vitro fertilization embryo transfer (IVF-ET).
A meta-analysis and systematic review of published articles evaluating the efficacy of myo-inositol in patients undergoing ovulation induction for ICSI or IVF-ET was performed.
Seven trials with 935 women were included. Myoinositol supplement was associated with significantly improved clinical pregnancy rate [95% confidence interval (CI), 1.04-1.96; P = .03] and abortion rate (95% CI, 0.08-0.50; P = .0006). Meanwhile, Grade 1 embryos proportion (95% CI, 1.10-2.74; P = .02), germinal vescicle and degenerated oocytes retrieved (95% CI, 0.11-0.86; P = .02), and total amount of ovulation drugs (95% CI, -591.69 to -210.39; P = .001) were also improved in favor of myo-inositol. There were no significant difference in total oocytes retrieved, MII stage oocytes retrieved, stimulation days, and E2 peak level.
Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. It may improve the quality of embryos, and reduce the unsuitable oocytes and required amount of stimulation drugs.
肌醇预处理是一种全新的方法，多项小型研究对其在辅助生殖中改善卵巢低反应的效果进行了评估。本研究旨在确定肌醇补充剂对接受卵胞浆内单精子注射（ICSI）或体外受精胚胎移植（IVF-ET）的排卵诱导不孕女性的疗效。
对已发表的评估肌醇在接受ICSI或IVF-ET排卵诱导患者中疗效的文章进行荟萃分析和系统评价。
纳入7项试验，共935名女性。补充肌醇与显著提高临床妊娠率[95%置信区间（CI），1.04 - 1.96；P = 0.03]和降低流产率（95% CI，0.08 - 0.50；P = 0.0006）相关。同时，优质胚胎比例（95% CI，1.10 - 2.74；P = 0.02）、获取的生发泡及退化卵母细胞数量（95% CI，0.11 - 0.86；P = 0.02）以及促排卵药物总量（95% CI，-591.69至-210.39；P = 0.001）也因肌醇而得到改善。在获取的卵母细胞总数、获取的MII期卵母细胞数、刺激天数和E2峰值水平方面无显著差异。
补充肌醇可提高接受ICSI或IVF-ET排卵诱导的不孕女性的临床妊娠率。它可能改善胚胎质量，减少不合适的卵母细胞数量及促排卵药物用量。
